← Back to Clinical Trials
Recruiting NCT06764069

NCT06764069 Feasibility Study to Evaluate an Intravascular Blood Continuous Glucose Sensor

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06764069
Status Recruiting
Phase
Sponsor Glucotrack
Condition Diabetes Mellitus
Study Type INTERVENTIONAL
Enrollment 10 participants
Start Date 2024-12-13
Primary Completion 2025-02-04

Trial Parameters

Condition Diabetes Mellitus
Sponsor Glucotrack
Study Type INTERVENTIONAL
Phase N/A
Enrollment 10
Sex ALL
Min Age 21 Years
Max Age 75 Years
Start Date 2024-12-13
Completion 2025-02-04
Interventions
Sensor Lead

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this early first in man clinical trial is to evaluate the safety of an implantable continuous blood glucose monitoring system in participants with Diabetes Mellitus. Safety will be assessed by looking at the absence of procedure or device related adverse events. Additionally, the surgical procedure and device performance will be evaluated. Key Research Questions: 1. Were there any adverse events associated with the insertion of the Sensor Lead? 2. Did Participants experience any device-related adverse events from the Sensor Lead insertion through the 96-hour observation period and subsequent removal of the Sensor Lead? 3. How effectively did the device capture data during the 96-hour wear period?

Eligibility Criteria

Inclusion Criteria: 1. Age 21 to 75 years old inclusive 2. Generally, in good health, as determined by the investigator 3. Clinical diagnosis or type 1 or type 2 diabetes as determined via medical records or source documentation by an individual qualified to make a medical diagnosis 4. Intensive Insulin Therapy - 3 plus injections/day (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) 5. HbA1c \<9.0 % in the last 3 months. 6. Study subject has adequate venous access as assessed by investigator or appropriate staff. 7. Willing to comply with study procedures and be admitted to hospital for up to 5 days. 8. Willing to perform up to 7 blood glucose (fingerstick) measurements a day using provided blood glucose meters and strips 9. Willing to wear subcutaneous continuous wear glucose sensor for the duration of the study 10. Willing to always carry study provided Android Phone during study 11. Access to internet for required periodic uploads of study device data 12. BMI in the range

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology